Novo Nordisk (NYSE: NVO) shares fell sharply by nearly 8% after the company’s capital markets day delivered an outlook that fell well short of investor expectations.
The Danish pharmaceutical giant failed to provide any meaningful short-term financial targets, leaving analysts and shareholders with more questions than answers about the company’s near-term trajectory.
Yahoo Finance Executive Editor Brian Sozzi flagged the disappointing presentation, warning that a wave of bearish analyst notes is likely to hit the market in the days ahead.
Sozzi noted that concerns are mounting around Novo Nordisk’s patent cliff, a looming threat that analysts fear could significantly erode the company’s revenue base in the years ahead.
Additional pressure is coming from the slow uptake of the company’s new weight loss pill, which struggled to gain traction in the weeks following its release earlier this year.
The contrast with rival Eli Lilly (NYSE: LLY), whose shares climbed more than 1% on the same day, underscores the widening competitive gap between the two pharmaceutical heavyweights in the weight loss drug market.
Novo Nordisk CEO Mike Dutar, speaking on the Yahoo Finance podcast Power Players, acknowledged that the company lost meaningful ground to its competitor, stating, “When you come second to market as our competitor did, it’s easier to look at the flaws and improve and adjust it.”
Dutar also outlined his vision for the company’s post-patent-cliff future, saying, “I would like to see a future after patent cliff where majority of semaglutide sold is sold by Novo Nordisk,” pointing to the company’s position as the world’s biggest generic insulin maker.
Despite those ambitions, Sozzi argued that earnings estimates for Novo Nordisk are likely to continue declining sharply, with bearish sentiment expected to dominate analyst coverage in the weeks to come.
For investors looking to maintain exposure to the weight loss drug sector, Sozzi pointed firmly toward Eli Lilly as the stronger bet, calling it the proven winner in the space and expecting another strong 12 months of performance from the Indianapolis-based drugmaker.
The divergence in share price performance on the day of Novo Nordisk’s capital markets day offers a stark visual representation of how investor confidence has shifted decisively in Eli Lilly’s favor over the past year.
Novo Nordisk, which was once considered a dominant force in the weight loss drug market and earned recognition as a company of the year just a couple of years ago, now faces a significantly more challenging road ahead as it works to reclaim lost ground.
